A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome

Fertility and Sterility

Volumn 86, Issue 6, 2006, Pages 1669-1675

  Chu, Micheline C ^a   Cosper, Pippa ^a   Nakhuda, Gary S ^a   Lobo, Rogerio A ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

insulin resistance; metabolic syndrome; oral estrogen; Postmenopausal; transdermal estrogen

Indexed keywords

ADIPONECTIN; ESTRADIOL; ESTROGEN; GHRELIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LIPID; RESISTIN;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HORMONAL THERAPY; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; METABOLIC SYNDROME X; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; STATISTICAL SIGNIFICANCE; UNIVERSITY HOSPITAL;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; BODY COMPOSITION; CYTOKINES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; MIDDLE AGED; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 33751160143     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2006.04.043     Document Type: Article

References (40)

1. Poehlman E.T., Toth M.J., and Gardner A.W. Changes in energy balance and body composition at menopause: a controlled longitudinal study. Ann Intern Med 123 (1995) 673-675
2. Spencer C.P., Godsland I.F., and Stevenson J.C. Is there a menopausal metabolic syndrome?. Gynecol Endocrinol 11 (1997) 341-355
3. Carr M.C. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 88 (2003) 2404-2411
4. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
5. Ford E.S., Giles W.H., and Mokdad A.H. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 27 (2004) 2444-2449
6. Wilson P.W., Kannel W.B., Silbershatz H., and D'Agostino R.B. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 159 (1999) 1104-1109
7. DeFronzo R., and Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14 (1991) 173-194
8. Ryan A.S., Berman D.M., Nicklas B.J., Sinha M., Gingerich R.L., Meneilly G.S., et al. Plasma adiponectin and leptin levels, body composition, and glucose utilization in adult women with wide ranges of age and obesity. Diabetes Care 26 (2003) 2383-2388
9. Fasshauer M., and Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 46 (2003) 1594-1603
10. Silha J.V., Krsek M., Skrha J.V., Sucharda P., Nyomba B.L., and Murphy L.J. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 149 (2003) 331-335
11. Purnell J.Q., Weigle D.S., Breen P., and Cummings D.E. Ghrelin levels correlate with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or cortisol levels in humans. J Clin Endocrinol Metab 88 (2003) 5747-5752
12. Lambrinoudaki I., Christodoulakos G., Panoulis C., Botsis D., Rizos D., Augoulea A., et al. Determinants of serum leptin levels in healthy postmenopausal women. J Endocrinol Invest 26 (2003) 1225-1230
13. Choi K.M., Lee J., Lee K.W., Seo J.A., Oh J.H., Kim S.G., et al. The associations between plasma adiponectin, ghrelin levels and cardiovascular risk factors. Eur J Endocrinol 150 (2004) 715-718
14. Chu M.C., Cosper P., Orio F., Carmina E., and Lobo R.A. Insulin resistance in postmenopausal women with metabolic syndrome and the measurements of adiponectin, leptin, resistin, and ghrelin. Am J Obstet Gynecol 194 (2006) 100-104
15. Lindheim S.R., Presser S.C., Ditkoff E.C., Vijod M.A., Stanczyk F.Z., and Lobo R.A. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 60 (1993) 664-667
16. Lindheim S.R., Duffy D.M., Kojima T., Vijodm M.A., Stanczyk F.Z., and Lobo R.A. The route of administration influences the effect of estrogen on insulin sensitivity in postmenopausal women. Fertil Steril 62 (1994) 1176-1180
17. Cucinelli F., Paparella P., Soranna L., Barini A., Cinque B., Mancuso S., et al. Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: relation to their insulinemic secretion. Eur J Endocrinol 140 (1999) 215-223
18. Cagnacci A., Soldani R., Carriero P.L., Paoletti A.M., Fioretti P., and Melis G.B. Effects of low doses of transdermal 17 beta-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 74 (1992) 1396-1400
19. Kanaya A.M., Herrington D., Vittinghoff E., Lin F., Grady D., Bittner V., et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 138 (2003) 1-9
20. Barrett-Connor E., Slone S., Greendale G., Kritz-Silverstein D., Espeland M., Johnson S.R., et al. The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women. Maturitas 27 (1997) 261-274
21. Sites C.K., L'Hommedieu G.D., Toth M.J., Brochu M., Cooper B.C., and Fairhurst P.A. The effect of hormone replacement therapy on body composition, body fat distribution, and insulin sensitivity in menopausal women: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 90 (2005) 2701-2707
22. Godsland I.F., Gangar K., Walton C., Cust M.P., Whitehead M.I., Wynn V., et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 42 (1993) 846-853
23. Spencer C.P., Godsland I.F., Cooper A.J., Ross D., Whitehead M.I., and Stevenson J.C. Effects of oral and transdermal 17beta-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. Metabolism 49 (2000) 742-747
24. O'Sullivan A., and Ho K. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab 80 (1995) 1783-1788
25. Manson J.E., Rimm E.B., Colditz G.A., Willett W.C., Nathan D.M., Arky R.A., et al. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus. Ann Epidemiol 2 (1992) 665-673
26. Margolis K.L., Bonds D.E., Rodabough R.J., Tinker L., Phillips L.S., Allen C., et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 47 (2004) 1175-1187
27. Coelingh Bennink H.J.T. Are all estrogens the same. Maturitas 47 (2004) 269-275
28. Lobo R.A. Absorption and metabolic effects of different types of estrogens and progestogens. Obstet Gynecol Clin North Am 14 (1987) 143-167
29. Lindheim S.R., Buchanan T.A., Duffy D.M., Vijod M.A., Kojima T., Stanczyk F.Z., et al. Comparison of estimates of insulin sensitivity in pre- and postmenopausal women using the insulin tolerance test and the frequently sampled intravenous glucose tolerance test. J Soc Gynecol Investig 1 (1994) 150-154
30. Katz A., Nambi S.S., Mather K., Baron A.D., Follmann D.A., Sullivan G., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85 (2000) 2402-2410
31. Stumvoll M., Mitrakou A., Pimenta W., Jenssen T., Yki-Jarvinen H., Van Haeften T., et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23 (2000) 295-301
32. Matsuda M., and DeFronzo R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22 (1999) 1462-1470
33. Lopes-Virella M., Stone P., Ellis S., and Colwell J. Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem 23 (1977) 882-884
34. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
35. Shiiya T., Nakazato M., Mizuta M., Date Y., Mondal M.S., Tanaka M., et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 87 (2002) 240-244
36. O'Sullivan A.J., Crampton L.J., Freund J., and Ho K.K. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J Clin Invest 102 (1998) 1035-1040
37. Ho K.K., O'Sullivan A.J., Wolthers T., and Leung K.C. Metabolic effects of oestrogens: impact of the route of administration. Ann Endocrinol (Paris) 64 (2003) 170-177
38. dos Reis C.M., de Melo N.R., Meirelles E.S., Vezozzo D.P., and Halpern A. Body composition, visceral fat distribution and fat oxidation in postmenopausal women using oral or transdermal oestrogen. Maturitas 46 (2003) 59-68
39. Di Carlo C., Tommaselli G.A., Sammartino A., Bifulco G., Nasti A., and Nappi C. Serum leptin levels and body composition in postmenopausal women: effects of hormone therapy. Menopause 11 (2004) 466-473
40. Godsland I.F. Oestrogens and insulin secretion. Diabetologia 48 (2005) 2213-2220